{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:27:34Z","timestamp":1794317254384,"version":"4.9.0"},"reference-count":112,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>This technical report accompanies the American Academy of Pediatrics (AAP) policy statement (https:\/\/doi.org\/10.1542\/peds.2026-079047) and recommendations for respiratory syncytial virus (RSV) immunization during the 2026\u20132027 RSV season. The rationale is presented for recommending immunization of all infants younger than 8 months born during or entering their first RSV season, unless the infant has documented protection from vaccination of the pregnant parent; and infants and children 8 through 19 months of age who are at high risk of severe RSV disease and entering their second RSV season. The report synthesizes current evidence on RSV epidemiology, disease burden, immunization effectiveness, safety, and cost-effectiveness in pediatric populations; including evidence supporting expansion of high-risk groups for second season administration. Additionally, the report provides an overview of available RSV immunization products, formulations, and coadministration with other immunizations.<\/jats:p>","DOI":"10.1542\/peds.2026-079049","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:02:17Z","timestamp":1788346937000},"source":"Crossref","is-referenced-by-count":1,"title":["Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report"],"prefix":"10.1542","volume":"158","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia S","family":"Pannaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica I","family":"Ardura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina A","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta L","family":"DeBiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert W","family":"Frenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Mary","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandy C","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latania","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M","family":"Milstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,10,26]]},"reference":[{"issue":"5","key":"2026111008074638900_r1","article-title":"Recommendations for the prevention of RSV disease in infants and children: policy statement","volume":"158","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2026","journal-title":"Pediatrics."},{"issue":"49","key":"2026111008074638900_r2","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1016\/j.vaccine.2011.08.005","article-title":"Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)","volume":"29","author":"Ahmed","year":"2011","journal-title":"Vaccine."},{"issue":"14","key":"2026111008074638900_r3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of respiratory syncytial virus\u2014United States, 2017\u20132023","volume":"72","author":"Hamid","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008074638900_r4","author":"Centers for Disease Control and Prevention"},{"issue":"6","key":"2026111008074638900_r5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7506a2","article-title":"Respiratory virus activity\u2014United States, July 1, 2024\u2013June 30, 2025","volume":"75","author":"Silk","year":"2026","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008074638900_r6","author":"Centers for Disease Control and Prevention"},{"key":"2026111008074638900_r7","volume-title":"AAP News.","author":"Jenco","year":"2026"},{"issue":"31","key":"2026111008074638900_r8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"2026111008074638900_r9","doi-asserted-by":"crossref","first-page":"e2559663","DOI":"10.1001\/jamanetworkopen.2025.59663","article-title":"Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab","volume":"9","author":"Acker","year":"2026","journal-title":"JAMA Netw Open."},{"key":"2026111008074638900_r10","article-title":"Weekly RSV Vaccination Dashboard","author":"Centers for Disease Control and Prevention"},{"issue":"1","key":"2026111008074638900_r11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12913-018-3041-x","article-title":"Pediatric admissions that include intensive care: a population-based study","volume":"18","author":"Ibiebele","year":"2018","journal-title":"BMC Health Serv Res."},{"key":"2026111008074638900_r12","first-page":"713","volume-title":"Red Book: 2024 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2024","edition":"33rd"},{"issue":"6","key":"2026111008074638900_r13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med."},{"issue":"2","key":"2026111008074638900_r14","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999\u20132018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"32","key":"2026111008074638900_r15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025","volume":"74","author":"Moulia","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"3","key":"2026111008074638900_r16","doi-asserted-by":"crossref","first-page":"e2023062574","DOI":"10.1542\/peds.2023-062574","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations Among Children &lt;5 Years Old: 2016 to 2020","volume":"153","author":"Curns","year":"2024","journal-title":"Pediatrics."},{"issue":"10340","key":"2026111008074638900_r17","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet."},{"issue":"6","key":"2026111008074638900_r18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis."},{"issue":"11","key":"2026111008074638900_r19","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/INF.0000000000004866","article-title":"Clinical Outcomes in Children &lt;5 Years of Age Hospitalized for Respiratory Syncytial Virus, COVID-19 or Influenza in the United States","volume":"44","author":"Andersen","year":"2025","journal-title":"Pediatr Infect Dis J."},{"issue":"12","key":"2026111008074638900_r20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00431-025-06596-6","article-title":"Risk factors associated with severe RSV disease among hospitalized children in the second year of life: a multicenter study","volume":"184","author":"Domany","year":"2025","journal-title":"Eur J Pediatr."},{"issue":"2","key":"2026111008074638900_r21","doi-asserted-by":"crossref","first-page":"e2022060435","DOI":"10.1542\/peds.2022-060435","article-title":"RSV Among American Indian and Alaska Native Children: 2019 to 2020","volume":"152","author":"Atwell","year":"2023","journal-title":"Pediatrics."},{"issue":"5","key":"2026111008074638900_r22","doi-asserted-by":"crossref","first-page":"e2025073923","DOI":"10.1542\/peds.2025-073923","article-title":"Recommendations for the prevention of RSV disease in infants and children: policy statement","volume":"156","author":"O\u2019Leary","year":"2025","journal-title":"Pediatrics."},{"key":"2026111008074638900_r23","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piag058","article-title":"RSV-associated hospitalizations among American Indian and Alaska Native children in Alaska and the Southwest United States, 2019-2023","author":"Hartman","year":"2026","journal-title":"J Pediatr Infect Dis Soc."},{"issue":"2","key":"2026111008074638900_r24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA."},{"issue":"9","key":"2026111008074638900_r25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"2026111008074638900_r26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/vaccines13020175","article-title":"Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND)","volume":"13","author":"Moreno-P\u00e9rez","year":"2025","journal-title":"Vaccines (Basel)."},{"key":"2026111008074638900_r27","author":"Jones"},{"issue":"2","key":"2026111008074638900_r28","doi-asserted-by":"crossref","first-page":"e2024069719","DOI":"10.1542\/peds.2024-069719","article-title":"Characteristics of Children Aged 0 to 23 Months Hospitalized With Respiratory Syncytial Virus","volume":"156","author":"Wang","year":"2025","journal-title":"Pediatrics."},{"issue":"7","key":"2026111008074638900_r29","doi-asserted-by":"crossref","first-page":"e2519410","DOI":"10.1001\/jamanetworkopen.2025.19410","article-title":"RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions","volume":"8","author":"Vi\u00f1eta Paramo","year":"2025","journal-title":"JAMA Netw Open."},{"key":"2026111008074638900_r30","author":"Osterman","year":"2024"},{"issue":"10433","key":"2026111008074638900_r31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","article-title":"Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data","volume":"403","author":"Wang","year":"2024","journal-title":"Lancet."},{"issue":"5","key":"2026111008074638900_r32","doi-asserted-by":"crossref","first-page":"e0197410","DOI":"10.1371\/journal.pone.0197410","article-title":"Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan","volume":"13","author":"Chi","year":"2018","journal-title":"PLoS One."},{"issue":"4","key":"2026111008074638900_r33","first-page":"e20240279","article-title":"Chronic lung disease of prematurity and bronchopulmonary dysplasia","volume":"50","author":"Souza","year":"2024","journal-title":"J Bras Pneumol."},{"issue":"6","key":"2026111008074638900_r34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr."},{"issue":"7","key":"2026111008074638900_r35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/pch\/pxy046","article-title":"Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis","volume":"23","author":"Butt","year":"2018","journal-title":"Paediatr Child Health."},{"issue":"2","key":"2026111008074638900_r36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jamapediatrics.2017.3792","article-title":"Association of age with risk of hospitalization for respiratory syncytial virus in preterm infants with chronic lung disease","volume":"172","author":"Winterstein","year":"2018","journal-title":"JAMA Pediatr."},{"issue":"4 Pt 1","key":"2026111008074638900_r37","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1542\/peds.104.4.993","article-title":"IMpact-RSV Study Group report","volume":"104","author":"Suresh","year":"1999","journal-title":"Pediatrics."},{"issue":"4","key":"2026111008074638900_r38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40121-016-0137-7","article-title":"Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease","volume":"5","author":"Paes","year":"2016","journal-title":"Infect Dis Ther."},{"issue":"4","key":"2026111008074638900_r39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","article-title":"Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease","volume":"5","author":"Figueras-Aloy","year":"2016","journal-title":"Infect Dis Ther."},{"issue":"22","key":"2026111008074638900_r40","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1016\/j.jacc.2025.11.020","article-title":"Outpatient management of isolated left-to-right shunt lesions in pediatric patients: 2026 ACC concise clinical guidance: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"87","author":"Sachdeva","year":"2026","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"2026111008074638900_r41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00246-017-1634-5","article-title":"Risk of Respiratory Syncytial Virus Hospitalization in the First and Second Years of Life in Pediatric Patients with Congenital Heart Disease","volume":"38","author":"Friedman","year":"2017","journal-title":"Pediatr Cardiol."},{"issue":"5","key":"2026111008074638900_r42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/INF.0000000000001357","article-title":"Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015)","volume":"36","author":"Li","year":"2017","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"2026111008074638900_r43","doi-asserted-by":"crossref","first-page":"e0172512","DOI":"10.1371\/journal.pone.0172512","article-title":"Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses","volume":"12","author":"Friedman","year":"2017","journal-title":"PLoS One."},{"issue":"10","key":"2026111008074638900_r44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jpids\/piab017","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations in Children With Neurological Disorders, 2006-2015","volume":"10","author":"Rose","year":"2021","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"3","key":"2026111008074638900_r45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.prrv.2009.06.003","article-title":"Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes","volume":"10","author":"Resch","year":"2009","journal-title":"Paediatr Respir Rev."},{"issue":"6","key":"2026111008074638900_r46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/INF.0b013e31805d01e3","article-title":"Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course","volume":"26","author":"Wilkesmann","year":"2007","journal-title":"Pediatr Infect Dis J."},{"issue":"6","key":"2026111008074638900_r47","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/ciy1010","article-title":"Respiratory syncytial virus prophylaxis in infants with congenital diaphragmatic hernia in the Canadian Respiratory Syncytial Virus Evaluation study of palivizumab, 2005-2017","volume":"69","author":"Kim","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"1","key":"2026111008074638900_r48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10096-018-3409-1","article-title":"Respiratory syncytial virus (RSV) infection in children with medical complexity","volume":"38","author":"Lim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"1","key":"2026111008074638900_r49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/INF.0000000000001340","article-title":"Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study","volume":"36","author":"Manzoni","year":"2017","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"2026111008074638900_r50","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s10096-019-03588-x","article-title":"Respiratory syncytial virus prophylaxis in infants with congenital diaphragmatic hernia in the Canadian Respiratory Syncytial Virus Evaluation study of palivizumab, 2005-2017","volume":"38","author":"Paes","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"8","key":"2026111008074638900_r51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/INF.0000000000002297","article-title":"Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab","volume":"38","author":"Wang","year":"2019","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"2026111008074638900_r52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00431-018-03308-1","article-title":"Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders","volume":"178","author":"Paes","year":"2019","journal-title":"Eur J Pediatr."},{"issue":"2","key":"2026111008074638900_r53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cis844","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis."},{"issue":"8","key":"2026111008074638900_r54","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dkt111","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections","volume":"68","author":"Shah","year":"2013","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"2026111008074638900_r55","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0000000000003855","article-title":"Viral Respiratory Tract Infections in the Immunocompromised Child","volume":"42","author":"Barr","year":"2023","journal-title":"Pediatr Infect Dis J."},{"issue":"2","key":"2026111008074638900_r56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1542\/peds.2007-1102","article-title":"Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age","volume":"121","author":"El Saleeby","year":"2008","journal-title":"Pediatrics."},{"issue":"6","key":"2026111008074638900_r57","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/MPH.0000000000000086","article-title":"Respiratory syncytial virus infections in children with cancer","volume":"36","author":"Chemaly","year":"2014","journal-title":"J Pediatr Hematol Oncol."},{"key":"2026111008074638900_r58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jpeds.2016.12.021","article-title":"Hospitalizations for Respiratory Syncytial Virus and Vaccine-Preventable Infections in the First 2 Years After Pediatric Liver Transplant","volume":"182","author":"Feldman","year":"2017","journal-title":"J Pediatr."},{"key":"2026111008074638900_r59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jpeds.2021.05.025","article-title":"Hospitalizations for Respiratory Syncytial Virus and Vaccine Preventable Infections following Pediatric Heart Transplantation","volume":"236","author":"Hayes","year":"2021","journal-title":"J Pediatr."},{"issue":"3","key":"2026111008074638900_r60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40121-017-0160-3","article-title":"Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases","volume":"6","author":"Manzoni","year":"2017","journal-title":"Infect Dis Ther."},{"issue":"8","key":"2026111008074638900_r61","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbmt.2013.05.005","article-title":"Mortality rates of human metapneumovirus and RSV lower respiratory tract infections in hematopoietic cell transplantation recipients","volume":"19","author":"Renaud","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2026111008074638900_r62","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1542\/peds.2007-0788","article-title":"Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study","volume":"120","author":"Bloemers","year":"2007","journal-title":"Pediatrics."},{"issue":"1","key":"2026111008074638900_r63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/INF.0b013e3181b34e52","article-title":"High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection","volume":"29","author":"Bloemers","year":"2010","journal-title":"Pediatr Infect Dis J."},{"issue":"7","key":"2026111008074638900_r64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/INF.0b013e3181d7ffa5","article-title":"Down syndrome and respiratory syncytial virus infection","volume":"29","author":"Megged","year":"2010","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"2026111008074638900_r65","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jpeds.2011.11.004","article-title":"Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study","volume":"160","author":"Zachariah","year":"2012","journal-title":"J Pediatr."},{"issue":"2","key":"2026111008074638900_r66","doi-asserted-by":"crossref","first-page":"020413","DOI":"10.7189\/jogh.07.020413","article-title":"Respiratory Syncytial Virus Network (ReSViNET). The burden of respiratory syncytial virus (RSV) associated acute ower respiratory infections in children with Down yndrome: a systematic review and meta-analysis","volume":"7","author":"Chan","year":"2017","journal-title":"J Glob Health."},{"key":"2026111008074638900_r67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2018.08.006","article-title":"Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis","volume":"203","author":"Mitra","year":"2018","journal-title":"J Pediatr."},{"issue":"3","key":"2026111008074638900_r68","doi-asserted-by":"crossref","first-page":"e20180225","DOI":"10.1542\/peds.2018-0225","article-title":"Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis","volume":"142","author":"Beckhaus","year":"2018","journal-title":"Pediatrics."},{"issue":"3","key":"2026111008074638900_r69","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jpeds.2014.11.058","article-title":"Children with Down syndrome are high-risk for severe respiratory syncytial virus disease","volume":"166","author":"Stagliano","year":"2015","journal-title":"J Pediatr."},{"issue":"2","key":"2026111008074638900_r70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ppul.20751","article-title":"Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis","volume":"43","author":"Giebels","year":"2008","journal-title":"Pediatr Pulmonol."},{"issue":"6","key":"2026111008074638900_r71","first-page":"CD007743","article-title":"Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis","author":"Robinson","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"2026111008074638900_r72","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ppul.22711","article-title":"Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis","volume":"48","author":"Winterstein","year":"2013","journal-title":"Pediatr Pulmonol."},{"key":"2026111008074638900_r73","author":"Jenco","year":"2025"},{"issue":"34","key":"2026111008074638900_r74","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"2026111008074638900_r75","first-page":"101196","article-title":"Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis","volume":"49","author":"Payne","year":"2025","journal-title":"Lancet Reg Health Am."},{"issue":"9","key":"2026111008074638900_r76","doi-asserted-by":"crossref","first-page":"e2533535","DOI":"10.1001\/jamanetworkopen.2025.33535","article-title":"Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season","volume":"8","author":"Pelletier","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"37","key":"2026111008074638900_r77","doi-asserted-by":"crossref","first-page":"580","DOI":"10.15585\/mmwr.mm7437a1","article-title":"Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants-24 states, December 2024-April 2025","volume":"74","author":"Zambrano","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"45","key":"2026111008074638900_r78","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.15585\/mmwr.mm7345a1","article-title":"Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024","volume":"73","author":"Lefferts","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"12","key":"2026111008074638900_r79","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1097\/INF.0000000000004942","article-title":"Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024","volume":"44","author":"Hammitt","year":"2025","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"2026111008074638900_r80","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis."},{"issue":"5","key":"2026111008074638900_r81","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"2026111008074638900_r82","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis."},{"issue":"5","key":"2026111008074638900_r83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/vaccines12050549","article-title":"Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d\u2019Aosta Region, Italy, in the 2023-2024 Epidemic Season","volume":"12","author":"Consolati","year":"2024","journal-title":"Vaccines (Basel)."},{"issue":"8","key":"2026111008074638900_r84","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/vaccines13080838","article-title":"Efficacy and Safety of Anti-Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab in Neonates: A Real-World Monocentric Study","volume":"13","author":"Costantino","year":"2025","journal-title":"Vaccines (Basel)."},{"issue":"22","key":"2026111008074638900_r85","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med."},{"key":"2026111008074638900_r86","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.17871","article-title":"RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season","volume-title":"JAMA.","author":"Senerth"},{"issue":"9","key":"2026111008074638900_r87","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity","volume":"386","author":"Domachowske","year":"2022","journal-title":"N Engl J Med."},{"issue":"45","key":"2026111008074638900_r88","doi-asserted-by":"crossref","first-page":"2500816","DOI":"10.2807\/1560-7917.ES.2025.30.45.2500816","article-title":"Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged &lt; 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025","volume":"30","author":"Savulescu","year":"2025","journal-title":"Euro Surveill."},{"key":"2026111008074638900_r89","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2026.101448","article-title":"Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada","author":"Carazo","year":"2026"},{"issue":"13","key":"2026111008074638900_r90","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for Prevention of RSV Disease in Healthy Infants","volume":"393","author":"Zar","year":"2025","journal-title":"N Engl J Med."},{"issue":"13","key":"2026111008074638900_r91","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMc2506107","article-title":"Clesrovimab in infants and children at increased risk for severe RSV disease","volume":"393","author":"Zar","year":"2025","journal-title":"N Engl J Med."},{"key":"2026111008074638900_r92","first-page":"e262760","article-title":"Clesrovimab in infants at increased risk for severe disease during 2 RSV seasons: a randomized clinical trial","author":"Zar","year":"2026","journal-title":"JAMA Pediatr."},{"key":"2026111008074638900_r93","year":"2026"},{"key":"2026111008074638900_r94","year":"2026"},{"issue":"9","key":"2026111008074638900_r95","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med."},{"issue":"26","key":"2026111008074638900_r96","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med."},{"issue":"5","key":"2026111008074638900_r97","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1097\/INF.0000000000004715","article-title":"Active post-marketing safety surveillance of nirsevimab administered to children in Western Australia, April-July 2024","volume":"44","author":"Carcione","year":"2025","journal-title":"Pediatr Infect Dis J."},{"issue":"6","key":"2026111008074638900_r98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/vaccines13060623","article-title":"Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain\u2019s 2023-2024 RSV Immunisation Campaign","volume":"13","author":"Estrella-Porter","year":"2025","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"2026111008074638900_r99","doi-asserted-by":"crossref","first-page":"2658377","DOI":"10.1080\/21645515.2026.2658377","article-title":"Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network","volume":"22","author":"Vi\u00f1eta Paramo","year":"2026","journal-title":"Hum Vaccin Immunother."},{"issue":"2","key":"2026111008074638900_r100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s40506-018-0163-y","article-title":"Transmission and Control of Respiratory Viral Infections in the Healthcare Setting","volume":"10","author":"Bonveh\u00ed","year":"2018","journal-title":"Curr Treat Options Infect Dis."},{"key":"2026111008074638900_r101","author":"Food and Drug Administration, Antimicrobial Drugs Advisory Committee"},{"key":"2026111008074638900_r102","doi-asserted-by":"crossref","first-page":"127591","DOI":"10.1016\/j.vaccine.2025.127591","article-title":"Safety of timely immunization with nirsevimab in hospitalized preterm infants","volume":"63","author":"Izquierdo","year":"2025","journal-title":"Vaccine."},{"key":"2026111008074638900_r103","author":"US Food and Drug Administration","year":"2025"},{"key":"2026111008074638900_r104","author":"Pfizer Inc"},{"key":"2026111008074638900_r105","author":"Centers for Disease Control and Prevention VSD","year":"2026"},{"key":"2026111008074638900_r106","author":"American College of Obstetricians and Gynecologists"},{"key":"2026111008074638900_r107","author":"American College of Obstetricians and Gynecologists","year":"2026"},{"issue":"4","key":"2026111008074638900_r108","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr."},{"issue":"15","key":"2026111008074638900_r109","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness Thresholds Used by Study Authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA."},{"key":"2026111008074638900_r110","author":"Institute for Clinical and Economic Review","year":"2026"},{"key":"2026111008074638900_r111","author":"Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices"},{"key":"2026111008074638900_r112","doi-asserted-by":"crossref","first-page":"708939","DOI":"10.3389\/fimmu.2021.708939","article-title":"Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper","volume":"12","author":"Esposito","year":"2021","journal-title":"Front Immunol."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-079049\/1979493\/pediatrics.2026079049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2026-079049\/1979493\/pediatrics.2026079049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:08:01Z","timestamp":1794316081000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/158\/5\/e2026079049\/208787\/Recommendations-for-the-Prevention-of-Respiratory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,26]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,26]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2026-079049","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,26]]},"article-number":"e2026079049"}}